This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Soliris' solid performance is likely to reflect in Alexion's (ALXN) second-quarter 2019 results.
Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?
by Zacks Equity Research
Alexion (ALXN) gains 30.7% on solid performance of lead drug Soliris and approval of Ultomiris.
Halozyme Therapeutics (HALO) Matches Q1 Earnings Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 0.00% and -20.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for March 4th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 4th
Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 50.00% and 1.65%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
by Zacks Equity Research
Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.
Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion's key drug like Soliris should drive growth in the fourth quarter of 2018.
Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
by Zacks Equity Research
Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.
Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure
by Zacks Equity Research
Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressure.
Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder
by Zacks Equity Research
Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.
Halozyme Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Halozyme Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 17.39% and -17.20%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Halozyme Therapeutics (HALO) Q3 Earnings Expected to Decline
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alexion's (ALXN) Earnings Beat Estimates in Q3, Guidance Up
by Zacks Equity Research
Alexion (ALXN) beats earnings estimates and marginally misses sales estimates in the third quarter of 2018. The company also inks a deal to acquire Syntimmune for $1.2 billion.
Halozyme Therapeutics (HALO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 27.27% and 11.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up
by Zacks Equity Research
ALexion (ALXN) beats both earnings and revenue estimates in the second quarter of 2018, and completes the acquisition of Wilson Therapeutics.
Alexion-Complement Pharma Tie Up to Treat Neuro Disorders
by Zacks Equity Research
Alexion (ALXN) teams up with Complement Pharma to co-develop its C6 inhibitor, CP010, for neurodegenerative disorders.
Options Traders Expect Huge Moves in Halozyme Therapeutics (HALO) Stock
by Zacks Equity Research
Halozyme Therapeutics (HALO) needs investors to pay close attention to the stock based on moves in the options market lately.
Bristol-Myers Yervoy Gets Positive CHMP Opinion for Melanoma
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) immuno-oncology drug Yervoy gets positive opinion from the CHMP of the European Medicines Agency for the treatment of pediatric patients of 12 years and older with unresectable or metastatic melanoma.
Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA
by Zacks Equity Research
Bristol-Myers (BMY) supplemental Biologics License Application (sBLA) for Opdivo and Yervoy combination for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma was accepted by the FDA.
The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals
Why Halozyme Therapeutics (HALO) Could Be Positioned for a Surge
by Zacks Equity Research
Halozyme Therapeutics (HALO) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
4 Top-Ranked Biotech Stocks Under $20 With Room for Growth
by Zacks Equity Research
We take a look at the biotech stocks with a potential for growth keeping in mind that the industry has witnessed a rebound in 2017 from last year's challenges.